Oliver McCammon
Stock Analyst at LifeSci Capital
(4.93)
# 164
Out of 4,339 analysts
72
Total ratings
64.9%
Success rate
86.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oliver McCammon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $38 | $7.91 | +380.40% | 9 | May 26, 2026 | |
| CATX Perspective Therapeutics | Maintained: Buy | $15 | $4.16 | +260.58% | 10 | May 16, 2026 | |
| CELC Celcuity | Rated: Buy | $165 | $134.26 | +22.90% | 12 | May 16, 2026 | |
| CADL Candel Therapeutics | Rated: Buy | $16 | $7.95 | +101.26% | 5 | May 16, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | $23 | $7.61 | +202.23% | 8 | May 16, 2026 | |
| INBX Inhibrx Biosciences | Maintained: Buy | $230 | $106.85 | +115.26% | 3 | May 16, 2026 | |
| JANX Janux Therapeutics | Rated: Buy | $60 | $14.40 | +316.67% | 12 | May 9, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintained: Buy | n/a | $19.20 | - | 13 | May 7, 2026 |
Corbus Pharmaceuticals Holdings
May 26, 2026
Maintained: Buy
Price Target: $38
Current: $7.91
Upside: +380.40%
Perspective Therapeutics
May 16, 2026
Maintained: Buy
Price Target: $15
Current: $4.16
Upside: +260.58%
Celcuity
May 16, 2026
Rated: Buy
Price Target: $165
Current: $134.26
Upside: +22.90%
Candel Therapeutics
May 16, 2026
Rated: Buy
Price Target: $16
Current: $7.95
Upside: +101.26%
Aura Biosciences
May 16, 2026
Maintained: Buy
Price Target: $23
Current: $7.61
Upside: +202.23%
Inhibrx Biosciences
May 16, 2026
Maintained: Buy
Price Target: $230
Current: $106.85
Upside: +115.26%
Janux Therapeutics
May 9, 2026
Rated: Buy
Price Target: $60
Current: $14.40
Upside: +316.67%
Monte Rosa Therapeutics
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $19.20
Upside: -